DERM - Dermira Stock Trading

Diabetes treatment was once a major part of drugmaker Sanofi (NASDAQ: SNY) , with its blockbuster Lantus bringing in $7 billion in annual sales as recently as six years ago. These days, Lantus' annual sales are more in the area of $3.2 billion, and in December, the company announced it w...

Targeting smaller "bolt-on" acquisitions in the range of $1 billion to $5 billion, Eli Lilly (NYSE: LLY) plans to expand its research and development pipeline by acquiring a company roughly every quarter. The company's CFO made these comments during the J.P. Morgan  Healthcare Confere...

Merger & acquisition activity at the 2020 J.P. Morgan Healthcare Conference has been a little disappointing, but not for a lack of effort on the part of  Eli Lilly   (NYSE: LLY) . The big pharma went beyond the call of duty by announcing the $1.1 billion acquisition of Dermira ...